Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: FANCI

Gene summary for FANCI

Gene summary.

Gene information	Species	Human
	Gene symbol	FANCI
	Gene ID	55215
	Gene name	FA complementation group I
	Gene Alias	KIAA1794
	Cytomap	15q26.1
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q9NVI1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55215	FANCI	HSIL_HPV_2	Human	Cervix	HSIL_HPV	1.44e-02	1.79e-01	0.0208
55215	FANCI	CCI_1	Human	Cervix	CC	2.71e-04	5.89e-01	0.528
55215	FANCI	CCI_2	Human	Cervix	CC	4.05e-07	7.61e-01	0.5249
55215	FANCI	CCI_3	Human	Cervix	CC	4.62e-03	4.67e-01	0.516
55215	FANCI	sample3	Human	Cervix	CC	5.51e-04	1.22e-01	0.1387
55215	FANCI	T3	Human	Cervix	CC	1.70e-02	1.47e-01	0.1389
55215	FANCI	LZE2T	Human	Esophagus	ESCC	4.42e-03	2.84e-01	0.082
55215	FANCI	LZE7T	Human	Esophagus	ESCC	1.06e-07	3.75e-01	0.0667
55215	FANCI	LZE24T	Human	Esophagus	ESCC	1.76e-03	8.25e-02	0.0596
55215	FANCI	LZE6T	Human	Esophagus	ESCC	8.86e-04	2.12e-01	0.0845
55215	FANCI	P2T-E	Human	Esophagus	ESCC	3.66e-13	3.04e-01	0.1177
55215	FANCI	P4T-E	Human	Esophagus	ESCC	3.56e-08	2.37e-01	0.1323
55215	FANCI	P8T-E	Human	Esophagus	ESCC	7.21e-03	1.85e-01	0.0889
55215	FANCI	P9T-E	Human	Esophagus	ESCC	3.19e-08	2.42e-01	0.1131
55215	FANCI	P10T-E	Human	Esophagus	ESCC	1.75e-09	2.95e-01	0.116
55215	FANCI	P15T-E	Human	Esophagus	ESCC	9.82e-11	3.07e-01	0.1149
55215	FANCI	P16T-E	Human	Esophagus	ESCC	6.46e-05	2.05e-01	0.1153
55215	FANCI	P17T-E	Human	Esophagus	ESCC	6.98e-03	1.00e-01	0.1278
55215	FANCI	P19T-E	Human	Esophagus	ESCC	1.99e-03	3.52e-01	0.1662
55215	FANCI	P20T-E	Human	Esophagus	ESCC	2.92e-03	1.03e-01	0.1124

Page: 1 2 3 4

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190332010	Cervix	CC	regulation of protein modification by small protein conjugation or removal	66/2311	242/18723	2.31e-10	3.46e-08	66
GO:003139610	Cervix	CC	regulation of protein ubiquitination	59/2311	210/18723	5.90e-10	7.51e-08	59
GO:00313983	Cervix	CC	positive regulation of protein ubiquitination	25/2311	119/18723	5.09e-03	3.01e-02	25
GO:19033224	Cervix	CC	positive regulation of protein modification by small protein conjugation or removal	28/2311	138/18723	5.26e-03	3.08e-02	28
GO:003139615	Cervix	HSIL_HPV	regulation of protein ubiquitination	33/737	210/18723	1.02e-11	6.81e-09	33
GO:190332015	Cervix	HSIL_HPV	regulation of protein modification by small protein conjugation or removal	34/737	242/18723	1.16e-10	4.31e-08	34
GO:003139812	Cervix	HSIL_HPV	positive regulation of protein ubiquitination	13/737	119/18723	8.24e-04	1.07e-02	13
GO:190332212	Cervix	HSIL_HPV	positive regulation of protein modification by small protein conjugation or removal	13/737	138/18723	3.16e-03	2.88e-02	13
GO:1903320111	Esophagus	ESCC	regulation of protein modification by small protein conjugation or removal	181/8552	242/18723	1.80e-20	2.60e-18	181
GO:0031396111	Esophagus	ESCC	regulation of protein ubiquitination	154/8552	210/18723	2.70e-16	2.04e-14	154
GO:190332216	Esophagus	ESCC	positive regulation of protein modification by small protein conjugation or removal	99/8552	138/18723	4.39e-10	1.16e-08	99
GO:003139816	Esophagus	ESCC	positive regulation of protein ubiquitination	82/8552	119/18723	2.41e-07	3.64e-06	82
GO:190332022	Liver	HCC	regulation of protein modification by small protein conjugation or removal	167/7958	242/18723	4.99e-17	4.72e-15	167
GO:003139622	Liver	HCC	regulation of protein ubiquitination	142/7958	210/18723	1.39e-13	7.81e-12	142
GO:19033221	Liver	HCC	positive regulation of protein modification by small protein conjugation or removal	94/7958	138/18723	9.87e-10	3.01e-08	94
GO:00313981	Liver	HCC	positive regulation of protein ubiquitination	79/7958	119/18723	1.18e-07	2.26e-06	79
GO:190332020	Oral cavity	OSCC	regulation of protein modification by small protein conjugation or removal	165/7305	242/18723	2.52e-20	3.99e-18	165
GO:003139620	Oral cavity	OSCC	regulation of protein ubiquitination	143/7305	210/18723	1.01e-17	9.80e-16	143
GO:19033227	Oral cavity	OSCC	positive regulation of protein modification by small protein conjugation or removal	88/7305	138/18723	3.24e-09	7.39e-08	88
GO:00313986	Oral cavity	OSCC	positive regulation of protein ubiquitination	75/7305	119/18723	9.46e-08	1.65e-06	75

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

FANCI

SNV

Missense_Mutation

c.3608C>G

p.Ser1203Cys

p.S1203C

Q9NVI1

protein_coding

deleterious(0)

probably_damaging(0.976)

TCGA-A8-A07W-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

exemestane

FANCI

SNV

Missense_Mutation

c.629N>C

p.Ile210Thr

p.I210T

Q9NVI1

protein_coding

deleterious(0)

possibly_damaging(0.72)

TCGA-A8-A08R-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

FANCI

SNV

Missense_Mutation

c.1082C>T

p.Ser361Leu

p.S361L

Q9NVI1

protein_coding

tolerated(0.11)

benign(0.027)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FANCI

SNV

Missense_Mutation

novel

c.2068G>A

p.Glu690Lys

p.E690K

Q9NVI1

protein_coding

tolerated(0.07)

benign(0.167)

TCGA-AC-A5XS-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

femara

FANCI

SNV

Missense_Mutation

c.1730C>T

p.Ser577Phe

p.S577F

Q9NVI1

protein_coding

deleterious(0.01)

possibly_damaging(0.812)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FANCI

SNV

Missense_Mutation

c.3407T>G

p.Met1136Arg

p.M1136R

Q9NVI1

protein_coding

deleterious(0.02)

benign(0.005)

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

FANCI

SNV

Missense_Mutation

c.615N>A

p.Met205Ile

p.M205I

Q9NVI1

protein_coding

deleterious(0.01)

benign(0.011)

TCGA-AR-A1AS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

FANCI

SNV

Missense_Mutation

novel

c.2086N>A

p.Glu696Lys

p.E696K

Q9NVI1

protein_coding

tolerated(0.31)

benign(0.037)

TCGA-GM-A2DO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

FANCI

SNV

Missense_Mutation

novel

c.608C>T

p.Ser203Phe

p.S203F

Q9NVI1

protein_coding

deleterious(0.04)

benign(0.397)

TCGA-PL-A8LV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

FANCI

insertion

Nonsense_Mutation

novel

c.2653_2654insGCTAAAAAATAGATAATAGAATATTA

p.Tyr885CysfsTer2

p.Y885Cfs*2

Q9NVI1

protein_coding

TCGA-A8-A0A4-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1